MedChoice CNS Pharma
Concise Prescribing Info
Management of schizophrenia & for the short-term treatment of mania associated w/ bipolar disorder.
Dosage/Direction for Use
Schizophrenia Initially 10 mg single daily dose, adjust dose to 5 mg daily according to response at intervals of not less than 1 wk w/in 5-20 mg daily. It is recommended that doses of ≥15 mg daily should be given after clinical re-assessment. Renal & moderate hepatic impairment Starting dose: 5 mg daily & increase dose w/ caution. Acute manic episodes Initially 10 or 15 mg daily, adjust dose to 5 mg daily & may subsequently be made at intervals of not less than 24 hr if necessary to w/in 5-20 mg daily, for 3-4 wk.
May be taken with or without food.
Special Precautions
Increased incidence of cerebrovascular adverse events w/ elderly patients w/ dementia-related psychosis. Possibility of suicide attempt to inherent in schizophrenia & bipolar I disorder. Monitor for signs & symptoms of hyperglycemia. Risk of hyperlipidemia. Regular monitoring of wt. Discontinue if neuroleptic malignant syndrome or tardive dyskinesia occurs. Patients w/ CV disease, history of low WBC count or drug-induced leucopenia/neutropenia, history of seizure or conditions that potentially lower the seizure threshold. May elevate prolactin levels. May impair judgment, thinking & motor skills. Pregnancy & lactation.
Adverse Reactions
Somnolence, dizziness, edema; wt gain, increased appetite; orthostatic hypotension; asymptomatic hyperprolactinemia; priapism; agranulocytosis, neutropenia; tardive dyskinesia, mania, neuroleptic malignant syndrome, convulsion.
Drug Interactions
Reduced antihypertensive action of guanethidine & other adrenergic neuron blockers. Potentiated adverse effects when given concomitantly w/ TCAs & other antiparkinsonian drugs. Increased risk of antipsychotic-induced extrapyramidal effects w/ metoclopramide. Akathisia & dystonia after alcohol consumption. Increased risk of arrhythmias w/ antiarrhythmics, antihistamine, antimalarial & cisapride; diuretics causing hypokalemia. Decreased plasma conc w/ antiepileptics. May affect plasma conc w/ CYP450 isoenzyme CYP1A2 inhibitors or substrates.
MIMS Class
ATC Classification
N05AH03 - olanzapine ; Belongs to the class of diazepines, oxazepines and thiazepines antipsychotics
Olzadin FC tab 10 mg
30's (P88.84/film-coated tab, P2,665.18/box)
Olzadin FC tab 5 mg
30's (P44.42/film-coated tab, P1,332.59/box)
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in